Literature DB >> 17452505

Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.

Gary F Mitchell1, Mark E Dunlap, Wayne Warnica, Anique Ducharme, J Malcolm O Arnold, Jean-Claude Tardif, Scott D Solomon, Michael J Domanski, Kathleen A Jablonski, Madeline M Rice, Marc A Pfeffer.   

Abstract

The Prevention of Events with Angiotensin Converting Enzyme inhibition (PEACE) trial evaluated angiotensin-converting enzyme inhibition with trandolapril versus placebo added to conventional therapy in patients with stable coronary disease and preserved left ventricular function. The PEACE hemodynamic substudy evaluated effects of trandolapril on pulsatile hemodynamics. Hemodynamic studies were performed in 300 participants from 5 PEACE centers a median of 52 months (range, 25 to 80 months) after random assignment to trandolapril at a target dose of 4 mg per day or placebo. Central pulsatile hemodynamics and carotid-femoral pulse wave velocity were assessed by using echocardiography, tonometry of the carotid and femoral arteries, and body surface transit distances. Patients randomly assigned to trandolapril tended to be older (mean+/-SD: 64.2+/-7.9 versus 62.9+/-7.7 years; P=0.14), with a higher body mass index (28.5+/-4.0 versus 27.8+/-3.9 kg/m(2); P=0.09) and lower ejection fraction (57.1+/-8.1% versus 58.7+/-8.4%; P<0.01). At the time of the hemodynamic substudy, the trandolapril group had lower mean arterial pressure (93.1+/-10.2 versus 96.3+/-11.3 mm Hg; P<0.01) and lower carotid-femoral pulse wave velocity (geometric mean [95% CI]: 10.4 m/s [10.0 to 10.9 m/s] versus 11.2 m/s [10.7 to 11.8 m/s]; P=0.02). The difference in carotid-femoral pulse wave velocity persisted (P<0.01) in an analysis that adjusted for baseline characteristics and follow-up mean pressure. In contrast, there was no difference in aortic compliance, characteristic impedance, augmentation index, or total arterial compliance. Angiotensin-converting enzyme inhibition with trandolapril produced a modest reduction in carotid-femoral pulse wave velocity, a measure of aortic wall stiffness, beyond what would be expected from blood pressure lowering or differences in baseline characteristics alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452505      PMCID: PMC2553625          DOI: 10.1161/HYPERTENSIONAHA.106.085738

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

1.  Carotid and femoral artery stiffness in relation to three candidate genes in a white population.

Authors:  E J Balkestein; J A Staessen; J G Wang; J J van Der Heijden-Spek; L M Van Bortel; C Barlassina; G Bianchi; E Brand; S M Herrmann; H A Struijker-Boudier
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

2.  Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.

Authors:  S Laurent; P Boutouyrie; R Asmar; I Gautier; B Laloux; L Guize; P Ducimetiere; A Benetos
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

3.  Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol.

Authors:  R G Asmar; G M London; M E O'Rourke; M E Safar
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

4.  Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo.

Authors:  S Kinlay; M A Creager; M Fukumoto; H Hikita; J C Fang; A P Selwyn; P Ganz
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

5.  Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients.

Authors:  A Benetos; S Gautier; S Ricard; J Topouchian; R Asmar; O Poirier; E Larosa; L Guize; M Safar; F Soubrier; F Cambien
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

6.  Angiotensin-converting enzyme gene polymorphism is associated with carotid arterial wall thickness in non-insulin-dependent diabetic patients.

Authors:  M Hosoi; Y Nishizawa; K Kogawa; T Kawagishi; T Konishi; K Maekawa; M Emoto; S Fukumoto; A Shioi; T Shoji; M Inaba; Y Okuno; H Morii
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

7.  Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study.

Authors:  J Topouchian; A M Brisac; B Pannier; E Vicaut; M Safar; R Asmar
Journal:  J Hum Hypertens       Date:  1998-03       Impact factor: 3.012

Review 8.  Resistance and conduit arteries following converting enzyme inhibition in hypertension.

Authors:  M E Safar; L M van Bortel; H A Struijker-Boudier
Journal:  J Vasc Res       Date:  1997 Mar-Apr       Impact factor: 1.934

9.  Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement.

Authors:  G F Mitchell; L A Moyé; E Braunwald; J L Rouleau; V Bernstein; E M Geltman; G C Flaker; M A Pfeffer
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

10.  Endothelial control of arterial distensibility is impaired in chronic heart failure.

Authors:  M W Ramsey; J Goodfellow; C J Jones; L A Luddington; M J Lewis; A H Henderson
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

View more
  35 in total

Review 1.  Noninvasive studies of central aortic pressure.

Authors:  Michael F O'Rourke; Audrey Adji
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 2.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

Review 3.  Translational physiology: from molecules to public health.

Authors:  Douglas R Seals
Journal:  J Physiol       Date:  2013-06-03       Impact factor: 5.182

Review 4.  Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?

Authors:  Henry Fok; J Kennedy Cruickshank
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

5.  Arterial stiffness in mild-to-moderate CKD.

Authors:  Ashish Upadhyay; Shih-Jen Hwang; Gary F Mitchell; Ramachandran S Vasan; Joseph A Vita; Plamen I Stantchev; James B Meigs; Martin G Larson; Daniel Levy; Emelia J Benjamin; Caroline S Fox
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

Review 6.  Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.

Authors:  János Nemcsik; István Kiss; András Tislér
Journal:  World J Nephrol       Date:  2012-02-06

7.  Pulse pressure and adverse outcomes in women: a report from the Women's Ischemia Syndrome Evaluation (WISE).

Authors:  R David Anderson; B Clay Sizemore; Genevieve M Barrow; B Delia Johnson; C Noel Bairey Merz; George Sopko; Gregory O von Mering; Eileen M Handberg; Wilmer W Nichols; Carl J Pepine
Journal:  Am J Hypertens       Date:  2008-09-18       Impact factor: 2.689

8.  Role of GRK4 in the regulation of arterial AT1 receptor in hypertension.

Authors:  Ken Chen; Chunjiang Fu; Caiyu Chen; Li Liu; Hongmei Ren; Yu Han; Jian Yang; Duofen He; Lin Zhou; Zhiwei Yang; Lianfeng Zhang; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2013-11-11       Impact factor: 10.190

9.  Arterial stiffness and cardiovascular events: the Framingham Heart Study.

Authors:  Gary F Mitchell; Shih-Jen Hwang; Ramachandran S Vasan; Martin G Larson; Michael J Pencina; Naomi M Hamburg; Joseph A Vita; Daniel Levy; Emelia J Benjamin
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

Review 10.  Clinical achievements of impedance analysis.

Authors:  Gary F Mitchell
Journal:  Med Biol Eng Comput       Date:  2008-10-14       Impact factor: 2.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.